bb-1701
Locally Advanced/Metastatic HER2 Positive Solid Tumors
Bliss Biopharmaceutical (Hangzhou) Co., LtdPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Locally Advanced/Metastatic HER2 Positive Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Same molecule, other indications
bb-1701 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →